Medexus Pharmaceuticals IncTSX:MDPView on OTCQX International
- LAST PRICE1.8200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.8000/ 10
- Ask / Lots2.0000/ 5
- Open / Previous Close0.0000 / 1.8200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDP |
|---|---|---|
| 09:34 ET | 100 | 1.92 |
| 09:41 ET | 600 | 1.89 |
| 09:54 ET | 400 | 1.9 |
| 10:26 ET | 1300 | 1.89 |
| 10:57 ET | 800 | 1.9 |
| 11:02 ET | 100 | 1.9 |
| 12:48 ET | 1200 | 1.88 |
| 01:01 ET | 100 | 1.87 |
| 01:14 ET | 100 | 1.87 |
| 01:32 ET | 1600 | 1.86 |
| 02:00 ET | 2300 | 1.85 |
| 02:42 ET | 100 | 1.85 |
| 02:51 ET | 100 | 1.85 |
| 03:00 ET | 1800 | 1.83 |
| 03:02 ET | 100 | 1.84 |
| 03:21 ET | 200 | 1.85 |
| 03:32 ET | 500 | 1.835 |
| 03:39 ET | 200 | 1.84 |
| 03:50 ET | 400 | 1.83 |
| 03:52 ET | 100 | 1.82 |
| 03:54 ET | 500 | 1.82 |
| 03:56 ET | 500 | 1.83 |
| 03:57 ET | 300 | 1.83 |
| 03:59 ET | 200 | 1.82 |
Apr 2, 2024
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 7:32AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:32AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Medexus Pharmaceuticals Inc | 44.9M | 5.0x | --- |
Vext Science Inc | 50.0M | 6.6x | -18.67% |
Acreage Holdings Inc | 33.1M | -0.4x | --- |
BellRock Brands Inc | 48.9M | -0.6x | --- |
Goodness Growth Holdings Inc | 111.2M | -2.9x | --- |
Medicus Pharma Ltd | 36.7M | -2.2x | --- |
Company Information
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.
Contact Information
- Headquarters
- 35 Nixon Road, Unit 1BOLTON, ON, Canada L7E 1K1
- Phone
- 514-762-2626
- Fax
- ---
Executives
- Independent Non-Executive Chairman of the Board
- Michael Mueller
- Director
- Ken D'entremont
- Chief Financial Officer
- Marcel Konrad
- General Counsel, Corporate Secretary
- Ian Wildgoose Brown
- General Manager, U.S. Operations
- Michael Adelman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $44.9M |
|---|---|
Revenue (TTM) | $159.4M |
Shares Outstanding | 24.5M |
Medexus Pharmaceuticals Inc does not pay a dividend. | |
Beta | 1.84 |
EPS | $0.37 |
Book Value | $1.53 |
P/E Ratio | 5.0x |
Price/Sales (TTM) | 0.3 |
Price/Cash Flow (TTM) | 2.8x |
Operating Margin | 10.97% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
